Inventiva ( (IVA) ) has issued an announcement.
Inventiva reported its financial results for the full year 2024, highlighting significant progress in its NATiV3 Phase 3 trial for lanifibranor, a treatment for MASH. The company secured a structured multi-tranche equity financing of up to €348 million, which will support the continuation of the trial. Despite a net loss of €184.2 million for 2024, Inventiva’s cash position improved significantly, reaching €96.6 million by the end of the year. The company also announced a pipeline prioritization plan, focusing exclusively on lanifibranor development, halting preclinical research, and reducing its workforce by 50%. This strategic shift aims to strengthen its position in the biopharmaceutical industry.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company that specializes in developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs. The company is listed on Euronext Paris and NASDAQ under the ticker IVA.
YTD Price Performance: 37.38%
Average Trading Volume: 9,632
Technical Sentiment Signal: Hold
Current Market Cap: $284M
Learn more about IVA stock on TipRanks’ Stock Analysis page.